Haemonetics Corporation Financial Summary (Unaudited data in thousands, except per share data) Consolidated Statements of Income for the Fourth Quarter of FY13 and FY12 3/30/2013 3/31/2012 % Inc/(Dec) As Reported As Repo

Three Months Ended 3/30/2013 3/31/2012 Whole Blood Acquisition Cost of Goods Sold $ 532 $ - Integration 8,195 - Y-Connector 984 - Restructuring and Transformation 2,760 2,774 HS Core Claims (37 ) (1,097 ) Transaction Costs 45 4,450 Arryx Disposition 4,791 - Contingent Consideration - - Total $ 17,270 $ 6,127 Twelve Months Ended 3/30/2013 3/31/2012 Whole blood acquisition cost of goods sold $ 15,715 $ - Integration 34,147 - Y-Connector 7,046 - Restructuring and Transformation 5,445 11,759 HS Core Claims (1,041 ) 3,112 Transaction Costs 3,181 4,450 Arryx Disposition 7,964 - Contingent Consideration - (1,580 ) Total $ 72,457 $ 17,741 11

They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K. Year Ended 3/30/2013 3/31/2012 Non-GAAP revenues GAAP revenue $ 891,990 $ 727,844 Foreign currency effects (57,670 ) (54,720 ) Non-GAAP revenue - constant currency $ 834,320 $ 673,124 Non-GAAP net income Non-GAAP net income, adjusted for restructuring, transformation costs and contingent consideration income $ 89,442 $ 78,400 Foreign currency effects (26,703 ) (19,694 ) Income tax associated with foreign currency effects 7,183 5,215 Non-GAAP net income - constant currency $ 69,922 $ 63,921 Non-GAAP net income per common share assuming dilution Non-GAAP net income per common share assuming dilution, adjusted for restructuring, transformation costs and contingent consideration income $ 1.71 $ 1.52 Foreign currency effects after tax per common share assuming dilution $ (0.37 ) $ (0.28 ) Non-GAAP net income per common share assuming dilution - constant currency $ 1.34 $ 1.24 10 Restructuring and Transformation Costs (in thousands) GAAP results include the following items which are excluded from adjusted results.

We measure different components of our business at constant currency. We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates. These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of 0.833 Euro to 1.00 US Dollar and 110 Yen to 1.00 US Dollar.

They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K. Three Months Ended 3/30/2013 3/31/2012 Non-GAAP revenues GAAP revenue $ 249,942 $ 186,670 Foreign currency effects (13,250 ) (14,614 ) Non-GAAP revenue - constant currency $ 236,692 $ 172,056 Non-GAAP net income Non-GAAP net income, adjusted for restructuring and transformation costs $ 25,064 $ 20,650 Foreign currency effects (7,105 ) (6,401 ) Income tax associated with foreign currency effects 1,532 1,586 Non-GAAP net income - constant currency $ 19,491 $ 15,835 Non-GAAP net income per common share assuming dilution Non-GAAP net income per common share assuming dilution, adjusted for restructuring and transformation costs $ 0.48 $ 0.40 Foreign currency effects after tax per common share assuming dilution $ (0.11 ) $ (0.09 ) Non-GAAP net income per common share assuming dilution - constant currency $ 0.37 $ 0.31 8 Reconciliation of Non-GAAP Measures for FY13 and FY12 Year Ended 3/30/2013 3/31/2012 Non-GAAP gross profit GAAP gross profit $ 428,131 $ 369,240 Whole blood acquisition cost of good sold adjustment 15,715 - Whole blood Y connector inventory reserves 7,046 - Restructuring and transformation costs (428 ) 1,510 Non-GAAP gross profit $ 450,464 $ 370,750 Non-GAAP R&D GAAP R&D $ 48,641 $ 36,801 Restructuring and transformation costs (8,345 ) (2,864 ) Non-GAAP R&D $ 40,296 $ 33,937 Non-GAAP S,G&A GAAP S,G&A $ 323,053 $ 245,261 Restructuring and transformation costs (41,780 ) (14,947 ) Non-GAAP S,G&A $ 281,273 $ 230,314 Non-GAAP operating expenses GAAP operating expenses $ 371,694 $ 280,482 Restructuring and transformation costs (50,125 ) (17,811 ) Contingent consideration income - 1,580 Non-GAAP operating expenses $ 321,569 $ 264,251 Non-GAAP operating income GAAP operating income $ 56,437 $ 88,758 Restructuring and transformation costs 72,458 19,321 Contingent consideration income - (1,580 ) Non-GAAP operating income $ 128,895 $ 106,499 Non-GAAP income before taxes GAAP income before taxes $ 49,897 $ 89,498 Restructuring and transformation costs 72,458 19,321 Contingent consideration income - (1,580 ) Non-GAAP income before taxes $ 122,355 $ 107,239 Non-GAAP net income GAAP net income $ 38,800 $ 66,886 Restructuring and transformation costs 72,458 19,321 Contingent consideration income - (1,580 ) Tax benefit associated with non-GAAP items (21,816 ) (6,227 ) Non-GAAP net income $ 89,442 $ 78,400 Non-GAAP net income per common share assuming dilution GAAP net income per common share assuming dilution $ 0.74 $ 1.30 Non-GAAP items after tax per common share assuming dilution $ 0.97 $ 0.22 Non-GAAP net income per common share assuming dilution $ 1.71 $ 1.52 9 Presented below are additional Constant Currency performance measures.

We measure different components of our business at constant currency. We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates. These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of 0.833 Euro to 1.00 US Dollar and 110 Yen to 1.00 US Dollar.

Non-GAAP Net Income and Earnings per Share The use of these non-GAAP measures allows management to monitor the level of net income and earnings per share excluding both the costs of our business transformation, as well as any related tax effects. We establish our budgets, forecasts, and performance targets on this basis. 6 Reconciliation of Non-GAAP Measures for the Fourth Quarter of FY13 and FY12 Three Months Ended 3/30/2013 3/31/2012 Non-GAAP gross profit GAAP gross profit $ 123,140 $ 94,612 Whole blood acquisition cost of good sold adjustment 532 - Whole blood Y connector inventory reserves 984 - Restructuring and transformation costs (428 ) 167 Non-GAAP gross profit $ 124,228 $ 94,779 Non-GAAP R&D GAAP R&D $ 17,818 $ 8,611 Restructuring and transformation costs (5,218 ) (962 ) Non-GAAP R&D $ 12,600 $ 7,649 Non-GAAP S,G&A GAAP S,G&A $ 87,614 $ 65,041 Restructuring and transformation costs (10,963 ) (4,998 ) Non-GAAP S,G&A $ 76,651 $ 60,043 Non-GAAP operating expenses GAAP operating expenses $ 105,432 $ 73,652 Restructuring and transformation costs (16,181 ) (5,960 ) Non-GAAP operating expenses $ 89,251 $ 67,692 Non-GAAP operating income GAAP operating income $ 17,708 $ 20,960 Restructuring and transformation costs 17,269 6,127 Non-GAAP operating income $ 34,977 $ 27,087 Non-GAAP income before taxes GAAP income before taxes $ 14,686 $ 21,329 Restructuring and transformation costs 17,269 6,127 Non-GAAP income before taxes $ 31,955 $ 27,456 Non-GAAP net income GAAP net income $ 12,561 $ 17,805 Restructuring and transformation costs 17,269 6,127 Tax benefit associated with non-GAAP items (4,766 ) (3,282 ) Non-GAAP net income $ 25,064 $ 20,650 Non-GAAP net income per common share assuming dilution GAAP net income per common share assuming dilution $ 0.24 $ 0.35 Non-GAAP items after tax per common share assuming dilution $ 0.24 $ 0.05 Non-GAAP net income per common share assuming dilution $ 0.48 $ 0.40 7 Presented below are additional Constant Currency performance measures.

We establish our budgets, forecasts, and performance targets excluding these costs. Non-GAAP Operating Income and Non-GAAP Income Before Income Taxes The use of these non-GAAP measures allows management to monitor the level of operating and total pre-tax profits without the costs of our business transformation. We establish our budgets, forecasts, and performance targets on this basis.

We establish our budgets, forecasts, and performance targets on this basis. Non-GAAP S,G&A and Non-GAAP Operating Expenses The use of this non-GAAP measure allows management to monitor the ongoing level of spend that is necessary to support the business in a period when we are not transforming our business or completing an acquisition of in-process research and development.

Additionally, a $7 million reserve for estimated inventory write-offs related to a whole blood Y connector quality issue was removed from GAAP cost of goods sold. We believe this information is useful for investors because it allows for an evaluation of the Company with a focus on the performance of our core operations. Non-GAAP Gross Profit The use of these non-GAAP measures allows management to monitor the level of total gross profits without the costs of our business transformation.

Our restructuring and transformation costs in fiscal 2013 are principally related to transaction and integration expenses associated with the Whole Blood Acquisition, as well as asset write-downs and other costs associated with exiting research and development activities related to operations originally acquired from Arryx, Inc. The cost of goods sold removed from GAAP expenses related to the Whole Blood Acquisition are mainly driven by the increase in fair value of acquired whole blood inventory required under purchase accounting standards.

These measures are used by management to monitor the financial performance of the business, make informed business decisions, and forecast future results. Performance targets for management are established based upon these non-GAAP measures. In the reconciliations below, we have removed restructuring and transformation costs and certain cost of goods sold related to the acquisition of Pall's Transfusion Medicine Business ("Whole Blood Acquisition") from our GAAP expenses.

A reconciliation is provided below that reconciles each non-GAAP financial measure with the most comparable GAAP measure. The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures. There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.